Table 3:

Association between the tumor mutational load^{^} and time to first treatment –HC MBL

		HC MBL (N=112)
		Total		Event
CLL-IPI	Mutated genes	N	col %	N	HR	95% CI	P
Overall*	None	59	52.7	5	1	reference
	Any	53	47.3	15	2.88	(1.01–8.21)	0.048
	0	59	52.6	5	1	reference
	1	35	31.3	7	2.07	(0.63–6.86)	0.23
	2+	18	16.1	8	4.09	(1.29–13.0)	0.017
	Cont.	112		20	1.53	(1.12–2.07)	0.007
	c-statistic				0.71	(0.59–0.83)
Low-intermediate risk CLL-IPI**	None	51	52	3	1	reference
	Any	47	48	13	2.74	(0.77–9.81)	0.12
	0	51	52	3	1	reference
	1	33	33.7	6	1.93	(0.48–7.76)	0.36
	2+	14	14.3	7	5.21	(1.20–22.6)	0.028
	Cont.	98		16	2.18	(1.19–4.01)	0.01
	c-statistic				0.70	(0.57–0.83)
High-very high risk CLL-IPI**	None	8	57.1	2	1	reference
	Any	6	42.9	2	2.18	(0.29–16.6)	0.45
	0	8	57.1	2	1	reference
	1	2	14.3	1	4.3	(0.24–75.8)	0.32
	2+	4	28.6	1	1.41	(0.11–17.8)	0.79
	Cont.	14		4	1.13	(0.71–1.81)	0.60
	c-statistic				0.61	(0.26–0.95)

HC MBL, monoclonal B-cell lymphocytosis; CLL-IP, CLL international prognostic index; HR, hazard ratio; CI, confidence interval; Cont., continuous

^{^}using 58 genes without counting mutations in TP53

^*Adjusted for CLL-IPI and sex

^**Adjusted for sex;